Menu Search
Equities

Adaptimmune Therapeutics PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
473A:DUS

Adaptimmune Therapeutics PLC

Actions
  • Price (EUR)0.0185
  • Today's Change0.003 / 19.35%
  • Shares traded12.00k
  • 1 Year change-96.54%
  • Beta2.4545
Data delayed at least 15 minutes, as of Feb 13 2026 07:11 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.

  • Revenue in USD (TTM)65.09m
  • Net income in USD-169.76m
  • Incorporated2014
  • Employees506.00
  • Location
    Adaptimmune Therapeutics PLC60 Jubilee Avenue, Milton ParkABINGDON OX14 4RXUnited KingdomGBR
  • Phone+44 123 543 0000
  • Websitehttps://www.adaptimmune.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.